文献速递血栓与止血

一种不依赖因子VIII的因子IX变体可减轻患者血浆中的A型血友病表型

A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma.
PubMed 文献 · J Thromb Haemost · 2023-02-28

研究用凝血酶生成和活化部分凝血活酶时间分析评估FIX-FIAV在21例A型血友病患者血浆中的效果。FIX-FIAV剂量依赖性地改善凝血酶生成滞后时间和活化部分凝血活酶时间,100%浓度可使严重型改善至中型、中型至轻型、轻型至正常。FIX-FIAV或可作为伴或不伴抑制物的A型血友病患者的潜在治疗。

要点

  • FIX-FIAV在严重型血浆中约400%至600%达最大效应,非严重型约200%至250%达最大效应。
  • 加入100% FIX-FIAV可使严重型FVIII等效活性从<0.01%升至2.9%,改善至中型。
  • 与现有A型血友病疗法联用未见实质性影响。

核心结论

  • FIX-FIAV能提高A型血友病患者血浆中的FVIII等效活性和凝血活性,从而减轻A型血友病表型。
  • 因此FIX-FIAV或可作为伴或不伴抑制物的A型血友病患者的潜在治疗。

研究设计与样本

  • 研究纳入21例年龄大于18岁的A型血友病患者血浆,其中轻型7例、中型7例、重型7例。
  • 将FIX-FIAV加入患者血浆,用FXIa触发的凝血酶生成滞后时间和活化部分凝血活酶时间评估,并以FVIII校准换算为FVIII等效活性。

主要发现

  • 凝血酶生成滞后时间和活化部分凝血活酶时间呈线性剂量依赖性改善,在严重型血浆中约400%至600% FIX-FIAV时达最大,在非严重型血浆中约200%至250%时达最大。
  • 向非严重型血浆加入抑制性抗FVIII抗体后,FIX-FIAV反应与严重型血浆相似,提示并证实FIX-FIAV的辅因子非依赖性贡献。
  • 加入100%(5 μg/mL)FIX-FIAV使严重型改善至中型(FVIII等效活性从<0.01%升至2.9%[IQR 2.3%-3.9%])。
  • 加入100%(5 μg/mL)FIX-FIAV使中型改善至轻型(FVIII等效活性从3.9%[IQR 3.3%-4.9%]升至16.1%[IQR 13.7%-18.1%])。
  • 加入100%(5 μg/mL)FIX-FIAV使轻型改善至正常(FVIII等效活性从19.8%[IQR 9.2%-24.0%]升至48.0%[IQR 34.0%-67.5%])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recombinant factor (F)IX-FIAV has previously been shown to function independently of activated FVIII (FVIIIa) and ameliorate the hemophilia A (HA) phenotype in vitro and in vivo. OBJECTIVES: The aim of this study was to assess the efficacy of FIX-FIAV in plasma from HA patients using thrombin generation (TG) and intrinsic clotting activity (activated partial thromboplastin time [APTT]) analyses. METHODS: Plasma obtained from 21 patients with HA (>18 years; 7 mild, 7 moderate, and 7 severe patients) was spiked with FIX-FIAV. The FXIa-triggered TG lag time and APTT were quantified in terms of FVIII-equivalent activity using FVIII calibration for each patient plasma. RESULTS: The linear, dose-dependent improvement in the TG lag time and APTT reached its maximum with approximately 400% to 600% FIX-FIAV in severe HA plasma and with approximately 200% to 250% FIX-FIAV in nonsevere HA plasma. The cofactor-independent contribution of FIX-FIAV was therefore suggested and confirmed by the addition of inhibitory anti-FVIII antibodies to nonsevere HA plasma, resulting in a FIX-FIAV response similar to severe HA plasma. Addition of 100% (5 μg/mL) FIX-FIAV mitigated the HA phenotype from severe to moderate (from <0.01% to 2.9% [IQR 2.3%-3.9%] FVIII-equivalent activity), from moderate to mild (3.9% [IQR 3.3%-4.9%] to 16.1% [IQR 13.7%-18.1%] FVIII-equivalent activity), and from mild to normal (19.8% [IQR 9.2%-24.0%] to 48.0% [IQR 34.0%-67.5%] FVIII-equivalent activity). No substantial effects were observed when combining FIX-FIAV with current HA therapies. CONCLUSION: FIX-FIAV is capable of increasing the FVIII-equivalent activity and coagulation activity in plasma from HA patients, thereby mitigating the HA phenotype. Hence, FIX-FIAV could serve as a potential treatment for HA patients with or without inhibitors.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Strijbis VJF, Romano LGR, Cheung KL, et al. A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma. J Thromb Haemost. 2023. PMID: 36863564. doi:10.1016/j.jtha.2023.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。